Fragrance Notes Spring 2017 - Page 36

D E VE L O P ME NT S Q1 2017 ADVOCACY This is an unprecedented time for industry with a relatively fast-moving government at the federal and state levels. IFRANA is well positioned to protect and promote the interest of our members. We are developing strategy to advocate both directly and with our allied trade association partners to mitigate risk and maximize opportunity for the fragrance industry. Our strategy also includes enhanced advocacy materials, messaging, and training for our Government & Legislative Affairs Executive Committee and Board of Directors. In addition, we are now leveraging public affairs and communications to amplify our advocacy efforts. Fragrance Ingredient Communication U.S. House Congressmen Frank Pallone (D-NJ) and Leonard Lance (R-NJ) plan to introduce a bipartisan cosmetics bill in the coming weeks. Amanda Nguyen met with staff from both offices and provided education related to fragrance and the fragrance industry. In Q1 2017, IFRANA continued to regularly meet with sponsors of H.R.575, a re-calibration of the Safe Cosmetics Modernization Act where similar education was provided. First introduced last year by Congressman Pete Sessions (R-TX), this legislation includes references to RIFM’s safety assessments and is supported by the Independent Cosmetic Manufacturers and Distributors (ICMAD). IFRANA has been communicating with ICMAD and will focus our efforts on any fragrance related portions of the bill. U.S. Senate Senator Diane Feinstein (D-CA) has indicated plans to reintroduce the Personal Care Products Safety Act in the coming weeks. We can expect to see some changes to the language. In particular, Senator Susan Collins (R-ME) intends to address topics related to small businesses. IFRANA is working closely with the Personal Care Pro ‘ՍΡ́ ½ΥΉ₯°…ΉM•ΈΈ•₯ΉΝΡ•₯»Šé½™™₯”)…Ήέ₯±°™½Ύ½Υȁ•™™½ΙΡ́½Έ…Ήδ™Ι…Ι…Ή”Ι•±…Ρ•Α½ΙΡ₯½ΉΜ½˜Ρ‘”‰₯±°Έ)MΡ…Ρ”%ΝΝΥ•Μ)%I9Ι•ΝΑ½Ή‘•ΡΌ …±₯™½ΙΉ₯„MΡ…Ρ”M•Ή…ѽȁI₯…Ι‘Ό1…Ι‡Šé₯ΉΡΙ½‘ՍΡ₯½Έ½˜) …±₯™½ΙΉ₯„M•Ή…Ρ” ₯±°€ΘΤΰ€‘M€ΘΤΰ€ƒŠLQ‘” ±•…Ή₯ΉœAΙ½‘ՍЁI₯‘ЁѼ-Ή½ά)ΠΈM€ΘΤΰ…ΡΡ•΅ΑΡ́ѼΑ₯¬Υΐέ‘•Ι”„ …±₯™½ΙΉ₯„•Ή•Ι…°ΝΝ•΅‰±δ ₯±°€‘(άΐΰ€±•™Π½™˜ƒŠLΙ•ΕΥ₯Ι₯ΉœΡ‘…Ё΅…ΉΥ™…ΡΥΙ•Ί‘₯͍±½Ν”„ΑΙ½‘ΥΣŠé₯ΉΙ•‘₯•ΉΡΜ)…ΉƒŠq½ΉΡ…΅₯Ή…ΉΡ́½˜½Ή•Ι»Št₯Έ½Ι‘•Θ½˜½Ή•ΉΡΙ…Ρ₯½Έ½ΈΡ‘”ΑΙ½‘ՍЁ±…‰•°)…Ή½Ή±₯Ή”ΈQ‘₯́ɕΕΥ₯Ι•΅•ΉΠ₯Ή±Υ‘•ΜΡ‘”₯ΉΙ•‘₯•ΉΡ́ΥΝ•₯Έ™Ι…Ι…Ή”)΅₯αΡΥΙ•ΜΈQ‘”‰₯±°₯́Ό΅ΝΑ½ΉΝ½Ι•‰δΡ‘”ΉΩ₯Ι½Ή΅•ΉΡ…°]½Ι­₯ΉœΙ½Υΐ°) Ι•…ΝЁ …Ή•ΘΥΉ°…Ή]½΅•»ŠéY½₯•Μ™½ΘΡ‘”…ΙΡ Έ(ΜΨ)II9 9=QLMAI%9€ΘΐΔά